Urinary dipeptidase 1 and trefoil factor 1 are promising biomarkers for early diagnosis of colorectal cancer.
Biomarker
Colorectal cancer
DPEP1
TFF1
Urine
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
12
01
2024
accepted:
24
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Currently utilized serum tumor markers and fecal immunochemical tests do not have sufficient diagnostic power for colorectal cancer (CRC) due to their low sensitivities. To establish non-invasive urinary protein biomarkers for early CRC diagnosis, we performed stepwise analyses employing urine samples from CRCs and healthy controls (HCs). Among 474 urine samples, 363 age- and sex-matched participants (188 HCs, 175 stage 0-III CRCs) were randomly divided into discovery (16 HCs, 16 CRCs), training (110 HCs, 110 CRCs), and validation (62 HCs, 49 CRCs) cohorts. Of the 23 urinary protein candidates comprehensively identified from mass spectrometry in the discovery cohort, urinary levels of dipeptidase 1 (uDPEP1) and Trefoil factor1 (uTFF1) were the two most significant diagnostic biomarkers for CRC in both training and validation cohorts using enzyme-linked immunosorbent assays. A urinary biomarker panel comprising uDPEP1 and uTFF1 significantly distinguished CRCs from HCs, showing area under the curves of 0.825-0.956 for stage 0-III CRC and 0.792-0.852 for stage 0/I CRC. uDPEP1 and uTFF1 also significantly distinguished colorectal adenoma (CRA) patients from HCs, with uDPEP1 and uTFF1 increasing significantly in the order of HCs, CRA patients, and CRC patients. Moreover, expression levels of DPEP1 and TFF1 were also significantly higher in the serum and tumor tissues of CRC, compared to HCs and normal tissues, respectively. This study established a promising and non-invasive urinary protein biomarker panel, which enables the early detection of CRC with high sensitivity.
Sections du résumé
BACKGROUND
BACKGROUND
Currently utilized serum tumor markers and fecal immunochemical tests do not have sufficient diagnostic power for colorectal cancer (CRC) due to their low sensitivities. To establish non-invasive urinary protein biomarkers for early CRC diagnosis, we performed stepwise analyses employing urine samples from CRCs and healthy controls (HCs).
METHODS
METHODS
Among 474 urine samples, 363 age- and sex-matched participants (188 HCs, 175 stage 0-III CRCs) were randomly divided into discovery (16 HCs, 16 CRCs), training (110 HCs, 110 CRCs), and validation (62 HCs, 49 CRCs) cohorts.
RESULTS
RESULTS
Of the 23 urinary protein candidates comprehensively identified from mass spectrometry in the discovery cohort, urinary levels of dipeptidase 1 (uDPEP1) and Trefoil factor1 (uTFF1) were the two most significant diagnostic biomarkers for CRC in both training and validation cohorts using enzyme-linked immunosorbent assays. A urinary biomarker panel comprising uDPEP1 and uTFF1 significantly distinguished CRCs from HCs, showing area under the curves of 0.825-0.956 for stage 0-III CRC and 0.792-0.852 for stage 0/I CRC. uDPEP1 and uTFF1 also significantly distinguished colorectal adenoma (CRA) patients from HCs, with uDPEP1 and uTFF1 increasing significantly in the order of HCs, CRA patients, and CRC patients. Moreover, expression levels of DPEP1 and TFF1 were also significantly higher in the serum and tumor tissues of CRC, compared to HCs and normal tissues, respectively.
CONCLUSIONS
CONCLUSIONS
This study established a promising and non-invasive urinary protein biomarker panel, which enables the early detection of CRC with high sensitivity.
Identifiants
pubmed: 38836911
doi: 10.1007/s00535-024-02110-1
pii: 10.1007/s00535-024-02110-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP19lm0203005
Organisme : Nagoya City University
ID : 2021102
Informations de copyright
© 2024. Japanese Society of Gastroenterology.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64.
doi: 10.3322/caac.21601
pubmed: 32133645
Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–14.
doi: 10.1056/NEJMoa1300720
pubmed: 24047060
Tao S, Haug U, Kuhn K, et al. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer. 2012;106:1424–30.
doi: 10.1038/bjc.2012.104
pubmed: 22454079
pmcid: 3326680
Xie YH, Gao QY, Cai GX, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine. 2017;25:32–40.
doi: 10.1016/j.ebiom.2017.10.005
pubmed: 29033369
pmcid: 5704049
Niedermaier T, Tikk K, Gies A, et al. Sensitivity of fecal immunochemical test for colorectal cancer detection differs according to stage and location. Clin Gastroenterol Hepatol. 2020;18(2920–8):e6.
Thomas DS, Fourkala EO, Apostolidou S, et al. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015;113:268–74.
doi: 10.1038/bjc.2015.202
pubmed: 26035703
pmcid: 4506388
Zhao M, Li M, Yang Y, et al. A comprehensive analysis and annotation of human normal urinary proteome. Sci Rep. 2017;7:3024.
doi: 10.1038/s41598-017-03226-6
pubmed: 28596590
pmcid: 5465101
Okuda Y, Shimura T, Iwasaki H, et al. Urinary microRNA biomarkers for detecting the presence of esophageal cancer. Sci Rep. 2021;11:8508.
doi: 10.1038/s41598-021-87925-1
pubmed: 33879806
pmcid: 8058072
Shimura T, Dagher A, Sachdev M, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015;8:240–8.
doi: 10.1158/1940-6207.CAPR-14-0229
pubmed: 25591790
Shimura T, Ebi M, Yamada T, et al. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017;8:29247–57.
doi: 10.18632/oncotarget.16453
pubmed: 28418926
pmcid: 5438727
Iwasaki H, Shimura T, Yamada T, et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol. 2019;54:1061–9.
doi: 10.1007/s00535-019-01601-w
pubmed: 31240436
Shimura T, Dayde D, Wang H, et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020;123:1656–64.
doi: 10.1038/s41416-020-01063-5
pubmed: 32934343
pmcid: 7686371
Iwasaki H, Shimura T, Kitagawa M, et al. A novel urinary miRNA biomarker for early detection of colorectal cancer. Cancers (Basel). 2022;14:461.
doi: 10.3390/cancers14020461
pubmed: 35053622
Shimura T, Iwasaki H, Kitagawa M, et al. Urinary cysteine-rich protein 61 and trefoil factor 3 as diagnostic biomarkers for colorectal cancer. Transl Oncol. 2019;12:539–44.
doi: 10.1016/j.tranon.2018.12.006
pubmed: 30611902
pmcid: 6319190
McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.
doi: 10.1200/JCO.2004.01.0454
pubmed: 16172462
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805–35.
doi: 10.1097/EDE.0b013e3181577511
pubmed: 18049195
Sobin LH, Gospodarowicz MK, Wittekind C, et al. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell; 2009.
Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003;75:663–70.
doi: 10.1021/ac026117i
pubmed: 12585499
Xin G, Wang M, Jiao LL, et al. Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria. Clin Chim Acta. 2004;350:35–9.
doi: 10.1016/j.cccn.2004.06.019
pubmed: 15530457
Ward DG, Nyangoma S, Joy H, et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 2008;6:19.
doi: 10.1186/1477-5956-6-19
pubmed: 18558005
pmcid: 2440369
Sun Y, Guo Z, Liu X, et al. Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis. Nat Commun. 2022;13:2757.
doi: 10.1038/s41467-022-30391-8
pubmed: 35589723
pmcid: 9119985
Zeng C, Qi G, Shen Y, et al. DPEP1 promotes drug resistance in colon cancer cells by forming a positive feedback loop with ASCL2. Cancer Med. 2023;12:412–24.
doi: 10.1002/cam4.4926
pubmed: 35670012
Zhang G, Schetter A, He P, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS ONE. 2012;7:e31507.
doi: 10.1371/journal.pone.0031507
pubmed: 22363658
pmcid: 3282755
McIver CM, Lloyd JM, Hewett PJ, et al. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett. 2004;209:67–74.
doi: 10.1016/j.canlet.2003.11.033
pubmed: 15145522
Park SY, Lee SJ, Cho HJ, et al. Dehydropeptidase 1 promotes metastasis through regulation of E-cadherin expression in colon cancer. Oncotarget. 2016;7:9501–12.
doi: 10.18632/oncotarget.7033
pubmed: 26824987
pmcid: 4891055
Yajima S, Ishii M, Matsushita H, et al. Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol. 2007;31:1029–37.
pubmed: 17912428
Liu Q, Deng J, Yang C, et al. DPEP1 promotes the proliferation of colon cancer cells via the DPEP1/MYC feedback loop regulation. Biochem Biophys Res Commun. 2020;532:520–7.
doi: 10.1016/j.bbrc.2020.08.063
pubmed: 32896379
Yusufu A, Shayimu P, Tuerdi R, et al. TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process. Int J Oncol. 2019;55:789–804.
pubmed: 31432157
pmcid: 6741840
Xiao P, Ling H, Lan G, et al. Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer. Clin Chim Acta. 2015;450:127–34.
doi: 10.1016/j.cca.2015.08.004
pubmed: 26265233
Rodrigues S, Rodrigue CM, Attoub S, et al. Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene. 2006;25:6628–36.
doi: 10.1038/sj.onc.1209665
pubmed: 16715141
Vocka M, Langer D, Petrtyl J, et al. Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. Neoplasma. 2015;62:470–7.
doi: 10.4149/neo_2015_056
pubmed: 25866228
Tokuhara T, Hattori N, Ishida H, et al. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006;12:3971–8.
doi: 10.1158/1078-0432.CCR-06-0338
pubmed: 16818694
Sanz B, Perez I, Beitia M, et al. Aminopeptidase N activity predicts 5-year survival in colorectal cancer patients. J Investig Med. 2015;63:740–6.
doi: 10.1097/JIM.0000000000000199
pubmed: 25929234
Wiese AH, Auer J, Lassmann S, et al. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev. 2007;31:282–95.
doi: 10.1016/j.cdp.2007.07.003
pubmed: 17936523
Lu X, Pan J, Li S, et al. Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. Cancer Biother Radiopharm. 2013;28:552–8.
pubmed: 23721165
pmcid: 3741425
Endo K, Kohnoe S, Tsujita E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005;25:3117–21.
pubmed: 16080575
Krijgsman D, Roelands J, Andersen MN, et al. Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. Mol Immunol. 2020;128:205–18.
doi: 10.1016/j.molimm.2020.10.012
pubmed: 33142138
Rasmussen L, Nielsen HJ, Christensen IJ. Early detection and recurrence of colorectal adenomas by combination of eight cancer-associated biomarkers in plasma. Clin Exp Gastroenterol. 2020;13:273–84.
doi: 10.2147/CEG.S251633
pubmed: 32884322
pmcid: 7434628